What’s Next? Five Things To Look Out For In December

Generics Bulletin previews the most noteworthy and anticipated events for December 2024.

What's Next Image

This month, an oral hearing in the US concerning the respective notices of appeal of Samsung Bioepis and Formycon is set to take place in litigation over their biosimilars to Regeneron’s Eylea (aflibercept).

On separate dates in June, a US district court in West Virginia, where all aflibercept-related litigation is currently playing out,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Preview

What’s Next? Five Things To Look Out For In May

 
• By 

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

What’s Next? Five Things To Look Out For In April

 
• By 

Generics Bulletin previews the most noteworthy and anticipated events for April 2025.

What’s Next? Five Things To Look Out For In March

 
• By 

Generics Bulletin previews the most noteworthy and anticipated events for March 2025.

What’s Next? Five Things To Look Out For In February

 
• By 

Generics Bulletin previews the most noteworthy and anticipated events for February 2025.

More from Business

Sandoz Streamlines More Trials As First-Half Biosimilars Sales Hit $1.5bn

 
• By 

Sandoz has revealed plans to streamline more biosimilar trials amid evolving regulatory moves towards minimizing the need for comparative efficacy studies. The disclosure was just one of many pipeline and portfolio updates provided as the firm delivered positive first-half results.

Amgen Stands Firm On IV Checkpoint Inhibitor Biosimilars

 
• By 

Amgen continues to advance its intravenous biosimilar programs for key immuno-oncology agents, including its ABP 234 biosimilar to Keytruda and ABP 206 biosimilar to Opdivo, despite growing interest in subcutaneous formulations enabled by hyaluronidase technology.

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

 
• By 

Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline.